Compare
UroGen Pharma Ltd. vs Gyre Therapeutics, Inc. vs Siga Technologies Inc vs Lifecore Biomedical, Inc.
| Latest fiscal year | UroGen Pharma Ltd. URGN | Gyre Therapeutics, Inc. GYRE | Siga Technologies Inc SIGA | Lifecore Biomedical, Inc. LFCR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-05-25 |
| Revenue | $109.79M | $116.59M | $94.57M | $128.87M |
| Revenue growth (YoY) | +21.4% | +10.2% | -31.8% | +0.5% |
| Gross margin | 88.7% | n/a | 68.6% (computed) | 31.3% |
| Operating margin | -113.7% | 9.9% | 25.1% | -13.4% |
| Net margin | -139.8% | 8.5% | 24.6% | -30.0% |
| Net income | -$153.49M | $9.88M | $23.28M | -$38.72M |
| EPS (Diluted) | n/a | $0.02 | $0.32 | -$1.27 |
| Operating cash flow | -$162.44M | $1.01M | $43.47M | -$206.0K |
| Free cash flow | -$162.73M | -$180.0K | n/a | -$13.62M |
| Cash & equivalents | $110.75M | $37.07M | $154.97M | $8.27M |
| Total assets | $200.46M | $166.13M | $219.47M | $239.34M |
| Total liabilities | $305.93M | $23.85M | $20.65M | $191.91M |
| Shareholders' equity | -$105.47M | $106.03M | $198.82M | $1.34M |
| Return on year-end equity | n/a | 9.3% | 11.7% | n/m |
| Shares outstanding | 48.35M | 91.31M | 71.61M | 37.03M |
Revenue, most recent five fiscal years
| Fiscal year | UroGen Pharma Ltd. | Gyre Therapeutics, Inc. | Siga Technologies Inc | Lifecore Biomedical, Inc. |
|---|---|---|---|---|
| Latest | $109.79M Ended 2025-12-31 | $116.59M Ended 2025-12-31 | $94.57M Ended 2025-12-31 | $128.87M Ended 2025-05-25 |
| 1 year earlier | $90.40M Ended 2024-12-31 | $105.76M Ended 2024-12-31 | $138.72M Ended 2024-12-31 | $128.26M Ended 2024-05-26 |
| 2 years earlier | $82.71M Ended 2023-12-31 | $113.45M Ended 2023-12-31 | $139.92M Ended 2023-12-31 | $103.27M Ended 2023-05-28 |
| 3 years earlier | $64.36M Ended 2022-12-31 | $102.29M Ended 2022-12-31 | $110.78M Ended 2022-12-31 | $111.27M Ended 2022-05-29 |
| 4 years earlier | $48.04M Ended 2021-12-31 | $7.34M Ended 2021-12-31 | $133.67M Ended 2021-12-31 | $100.87M Ended 2021-05-30 |